The disclosure describes a method of preparing pyridazinone derivatives comprising contacting a compound of formula (I) or a salt thereof:

##STR00001##

with a compound of formula (II) or a salt thereof:

##STR00002##

to form a compound of formula (III) or a salt thereof:

##STR00003##

A compound of formula (III) can then be converted to a compound of formula (IV):

##STR00004##

which can be used for preparing compounds for treating a liver disease or disorder, or a lipid disease or disorder.

The disclosure describes a method of preparing pyridazinone derivatives comprising contacting a compound of formula (I) or a salt thereof:

##STR00001##

with a compound of formula (II) or a salt thereof:

##STR00002##

to form a compound of formula (III) or a salt thereof:

##STR00003##

A compound of formula (III) can then be converted to a compound of formula (IV):

##STR00004##

which can be used for preparing compounds for treating a liver disease or disorder, or a lipid disease or disorder.

The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in .sup.18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in .sup.18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasome production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.

##STR00001##

The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasome production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.

##STR00001##

The invention relates to pyridazinone and pyridone compounds having formula (I) or (I), and pharmaceutically acceptable salts, hydrates, and solvates thereof ##STR00001##
wherein R.sub.1/R.sub.4 and X and X.sub.3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.

The invention relates to pyridazinone and pyridone compounds having formula (I) or (I), and pharmaceutically acceptable salts, hydrates, and solvates thereof ##STR00001##
wherein R.sub.1/R.sub.4 and X and X.sub.3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.

The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TR? mutation.

The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TR? mutation.